Skip to content
Sign in

MDGL · NASDAQ

Madrigal Pharmaceuticals (MDGL) Stock Price & Fundamentals

$1,066.28+0.66%+$6.99End-of-day price as of Oct 9, 2026

Madrigal Pharmaceuticals (MDGL) closed at $1,066.28 on Oct 9, 2026, up 0.66% from the previous close of $1,059.29.

Share price, past year

1Y +15.53%

52-week range $915.65 – $1,142.26. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$1,066.28
Sep 30, 2026$1,049.37
Aug 31, 2026$1,042.22
Jul 31, 2026$1,072.14
Jun 30, 2026$1,090.03
May 29, 2026$1,089.63
Apr 30, 2026$1,097.32
Mar 31, 2026$1,088.48
Feb 27, 2026$1,020.99
Jan 30, 2026$1,010.46
Dec 31, 2025$967.23
Nov 28, 2025$955.99
Oct 31, 2025$938.61

Key statistics

Market cap
$24.62B
P/E (TTM)
—
EPS (TTM)
−$11.28
Revenue (TTM)
$1.28B
Net income (TTM)
−$325.10M
Shares outstanding
23.1M
Dividend yield
—
52-week range
$915.65 – $1,142.26

Madrigal Pharmaceuticals's market cap is $24.62B, based on a share price of $1,066.28 and 23.1M shares outstanding as of Jun 30, 2026.

Financials

Madrigal Pharmaceuticals reported revenue of $958.40M for fiscal 2025, up 432.05% from fiscal 2024.

Madrigal Pharmaceuticals reported a net loss of $288.28M in fiscal 2025.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY12FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Madrigal Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$958.40M+432.1%−$288.28M−30.1%−$10.15−$190.02M
FY2024ended Dec 31, 2024$180.13M—−$465.89M−258.6%−$17.31−$457.03M
FY2023ended Dec 31, 2023$0.00—−$373.63M—−$17.33−$325.71M
FY2022ended Dec 31, 2022$0.00—−$295.35M—−$17.23−$225.07M
FY2021ended Dec 31, 2021$0.00—−$241.85M—−$14.63−$184.13M
FY2020ended Dec 31, 2020$0.00—−$202.24M—−$13.09−$157.90M
FY2019ended Dec 31, 2019$0.00—−$83.95M—−$5.45−$41.80M
FY2018ended Dec 31, 2018$0.00—−$32.81M—−$2.22−$25.53M
FY2017ended Dec 31, 2017$0.00−100.0%−$31.15M—−$2.54−$22.44M
FY2012ended Dec 31, 2012$147.00K—————
Madrigal Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$364.25M−$57.94M−$1.99
Q1 FY2026ended Mar 31, 2026$311.34M−$94.39M−$3.25
Q4 FY2025ended Dec 31, 2025$321.08M−$58.58M−$2.03
Q3 FY2025ended Sep 30, 2025$287.27M−$114.19M−$4.01
Q2 FY2025ended Jun 30, 2025$212.80M−$42.28M−$1.50
Q1 FY2025ended Mar 31, 2025$137.25M−$73.24M−$2.61
Q4 FY2024ended Dec 31, 2024$103.32M−$59.42M$2.09
Q3 FY2024ended Sep 30, 2024$62.18M−$106.96M−$4.92

Company profile

Name
Madrigal Pharmaceuticals, Inc.
Ticker
MDGL
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
1001 Conshohocken State Road, Suite 2-350, West Conshohocken, PA
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001157601

Recent SEC filings

Frequently asked questions

What is Madrigal Pharmaceuticals's stock price?

Madrigal Pharmaceuticals (MDGL) closed at $1,066.28 on Oct 9, 2026, up 0.66% from the previous close of $1,059.29.

What is Madrigal Pharmaceuticals's market cap?

Madrigal Pharmaceuticals's market cap is $24.62B, based on a share price of $1,066.28 and 23.1M shares outstanding as of Jun 30, 2026.

How much revenue does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals reported revenue of $958.40M for fiscal 2025, up 432.05% from fiscal 2024.

Does Madrigal Pharmaceuticals pay a dividend?

Madrigal Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Madrigal Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures